Shin Nippon Biomedical Laboratories, Ltd. is a specialist contract research organization offering comprehensive nonclinical services to support early‐stage drug development. The company’s core activities include safety pharmacology, toxicology, pharmacokinetics, bioanalysis and ADME studies conducted under stringent GLP and quality assurance standards.
Founded in 1991 and headquartered in Kagoshima, Japan, Shin Nippon Biomedical Laboratories operates multiple research facilities across Japan. These sites are equipped for rodent and non‐rodent studies and house advanced analytical laboratories, allowing the company to address a wide array of preclinical testing needs for pharmaceutical, biotechnology and agrochemical clients.
Leveraging experienced scientific teams and state‐of‐the‐art infrastructure, Shin Nippon Biomedical Laboratories designs customized study protocols to generate reliable safety and efficacy data. The company’s services span from exploratory toxicology and dose‐range finding to pivotal GLP studies necessary for regulatory submissions in major markets.
Shin Nippon Biomedical Laboratories serves both domestic and international biopharmaceutical customers, maintaining strategic partnerships to extend its global footprint. By adhering to global regulatory guidelines and emphasizing data integrity, the company aims to accelerate drug candidate evaluation and facilitate smoother transitions into clinical development.
AI Generated. May Contain Errors.